bih.button.backtotop.text
BROWSE BY TEST NAME
#
%
1
2
3
5
8
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code (รหัสการทดสอบ):
090-31-3010

Order Name (ชื่อการทดสอบ):
Insulin-Like Growth Factor-1, Mass Spectrometry, Serum **

 
Specimen / Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ Plain blood (Red top) 6 mL, 2 tubes
NECESSARY INFORMATION 
Indicate patient's age and sex
 
Turnaround Time (ระยะเวลารอผล):
Receive specimen to report within 14 days
 
Useful For (ประโยชน์การทดสอบ):
Evaluation of growth disorders
Evaluation of growth hormone deficiency or excess in children and adults
Monitoring of recombinant human growth hormone treatment
Follow-up of individuals with acromegaly and gigantism
 
Methodology (วิธีการทดสอบ):
Liquid Chromatography-Mass Spectrometry (LC/MS)
 
AliasesName (ชื่อเรียกอื่นๆ) :

Somatomedin-C
 

 
 
 
Test Code (รหัสการทดสอบ):
090-31-3010

Order Name (ชื่อการทดสอบ):
Insulin-Like Growth Factor-1, Mass Spectrometry, Serum **

 
Collection Specimen Or Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ Plain blood (Red top) 6 mL, 2 tubes
NECESSARY INFORMATION 
Indicate patient's age and sex
 
Specimen Testing Type (สิ่งส่งตรวจที่ใช้ในการทดสอบ):
Serum, minimum volume 1 mL x 2 tubes

NECESSARY INFORMATION 
Indicate patient's age and sex
 
Sub Mission Container (ภาชนะส่งตรวจ):
Plastic tube
 
Specimen Stabillity (ความคงตัวของสิ่งส่งตรวจ):
Specimen Type Temperature Time
Serum Frozen (preferred) 28 days
Serum Ambient 72 hours
Serum Refrigerated 72 hours
 
 
 
Test Code (รหัสการทดสอบ):
090-31-3010

Order Name (ชื่อการทดสอบ):
Insulin-Like Growth Factor-1, Mass Spectrometry, Serum **

 
Method detail (วิธีการทดสอบ):
Liquid Chromatography-Mass Spectrometry (LC/MS)
 
Schedule (ตารางการทดสอบ):
N/A **Sent out to MAYO, USA 
 
Turnaround Time (ระยะเวลารอผล):
Receive specimen to report within 14 days
 
Performing Location (หน่วยงานที่ทำการทดสอบ):
MAYO Laboratory
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code (รหัสการทดสอบ):
090-31-3010

Order Name (ชื่อการทดสอบ):
Insulin-Like Growth Factor-1, Mass Spectrometry, Serum **

 
 
Clinical Information (ข้อมูลทางคลินิก):
Insulin-like growth factor 1 (IGF1) is a 70-amino acid polypeptide (molecular weight 7649 Da; Uniprot Accession P05019 [aa 49-118]). IGF1 is a member of a family of closely related growth factors with high homology to insulin that signal through a corresponding group of highly homologous tyrosine kinase receptors. IGF1 is produced by many tissues, but the liver is the main source of circulating IGF1. IGF1 is the major mediator of the anabolic and growth-promoting effects of growth hormone (GH). IGF1 is transported by IGF-binding proteins, in particular insulin-like growth factor-binding protein 3 (IGFBP3), which also controls its bioavailability and half-life. Noncomplexed IGF1 and IGFBP3 have short half-lives (t1/2) of 10 and 30 to 90 minutes, respectively, while the IGFBP3/IGF1 complex is cleared with a much slower t1/2 of 12 hours.
 
The secretion patterns of IGF1 and IGFBP3 mimic each other, their respective syntheses being controlled by GH. Unlike GH secretion, which is pulsatile and demonstrates significant diurnal variation, IGF1 and IGFBP3 levels show only minor fluctuations. IGF1 and IGFBP3 serum levels, therefore, represent a stable and integrated measurement of GH production and tissue effect.
 
Low IGF1 and IGFBP3 levels are observed in GH deficiency or GH resistance. If acquired in childhood, these conditions result in short stature.
 
Childhood GH deficiency can be an isolated abnormality or associated with deficiencies of other pituitary hormones. Some of the latter cases may be due to pituitary or hypothalamic tumors, or result from cranial radiation or intrathecal chemotherapy for childhood malignancies.
 
Most GH resistance in childhood is mild-to-moderate, with causes ranging from poor nutrition to severe systemic illness (eg, renal failure). These individuals may have IGF1 and IGFBP3 levels within the reference range. Severe childhood GH resistance is rare and usually due to defects of the GH-receptor, its downstream signaling cascades, or deleterious mutations in IGF1, its binding proteins, or its receptor signaling cascades.
 
Both GH deficiency and mild-to-moderate GH resistance can be treated with recombinant human GH (rhGH) injections, while severe resistance will usually not respond to GH. However, such patients might respond to recombinant IGF1 therapy, unless the underlying defect is in the IGF1 receptor or its downstream signaling systems.
 
The exact prevalence and causes of adult GH resistance are uncertain, but adult GH deficiency is seen mainly in pituitary tumor patients. It is associated with decreased muscle bulk and increased cardiovascular morbidity and mortality, but replacement therapy remains controversial.
 
Elevated serum IGF1 and IGFBP3 levels often indicate a sustained overproduction of GH, or excessive rhGH therapy. Endogenous GH excess is caused mostly by GH-secreting pituitary adenomas, resulting in gigantism, if acquired before epiphyseal closure, and in acromegaly thereafter. Both conditions are associated with generalized organomegaly, hypertension, diabetes, cardiomyopathy, osteoarthritis, compression neuropathies, a mild increase in cancer risk (breast, colon, prostate, lung), and diminished longevity. It is plausible, but unproven, that long-term rhGH overtreatment may result in similar adverse outcomes.
 
Malnutrition results in low serum IGF1 concentrations, which recover with restoration of adequate nutrition.
 
Reference Value (ค่าอ้างอิง):

Units: ng/mL
(Referenge range provide in report) 

 
Clinical Reference (เอกสารอ้างอิง):
www.mayomedicallaboratories.com (Retrieved: 22 Mar 2022)